X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Phio intends to use the net proceeds from the offering for the development of its immuno-oncology programs including, PH-762, an INTASYL compound that reduces the expression of PD-1, a protein that inhibits T cells' ability to kill cancer cells.
Lead Product(s): PH-762
Therapeutic Area: Oncology Product Name: PH-762
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: H.C. Wainwright & Co.
Deal Size: $4 million Upfront Cash: Undisclosed
Deal Type: Public Offering June 02, 2023
Details:
Phio intends to use the net proceeds for the development of its immuno-oncology programs, including PH-762, an INTASYL compound that reduces the expression of cell death Protein 1, a protein that inhibits T cells’ ability to kill cancer cells.
Lead Product(s): PH-762
Therapeutic Area: Oncology Product Name: PH-762
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: H.C. Wainwright & Co.
Deal Size: $4 million Upfront Cash: Undisclosed
Deal Type: Public Offering May 31, 2023
Details:
PH-762 is an INTASYL compound that reduces the expression of PD-1, that inhibits T cells' ability to kill cancer cells. Decreasing the expression of PD-1 increases the capacity of T cells to kill cancer cells. It is being investigated for skin carcinomas.
Lead Product(s): PH-762
Therapeutic Area: Oncology Product Name: PH-762
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 24, 2023
Details:
PH-762 is an INTASYL compound that reduces the expression of PD-1, that inhibits T cells' ability to kill cancer cells. Decreasing the expression of PD-1 increases the capacity of T cells to kill cancer cells. It is being investigated for skin carcinomas.
Lead Product(s): PH-762
Therapeutic Area: Oncology Product Name: PH-762
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 16, 2023
Details:
Phio intends to use the net proceeds from the offering for the development of its immuno-oncology programs, including PH-762, an INTASYL™ compound that reduces the expression of PD-1, a protein that inhibits T cells’ ability to kill cancer cells.
Lead Product(s): PH-762
Therapeutic Area: Oncology Product Name: PH-762
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: H.C. Wainwright & Co.
Deal Size: $2.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering April 18, 2023
Details:
PH-762 is an INTASYL compound that reduces the expression of cell death Protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells. Decreasing the expression of PD-1 increases the capacity of T cells to kill cancer cells.
Lead Product(s): PH-762
Therapeutic Area: Oncology Product Name: PH-762
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 10, 2023
Details:
PH-762 is an INTASYL™ compound, which suppresses PD-1 expression, a protein that inhibits T cells’ ability to kill cancer cells. It is being developed as a standalone drug therapy and also in combination with ACT.
Lead Product(s): PH-762
Therapeutic Area: Oncology Product Name: PH-762
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 06, 2023
Details:
INTASYL compounds are chemically modified siRNAs that are designed to provide efficient, spontaneous cellular uptake and potent, long lasting intracellular activity targeting a broad range of cell types and tissues.
Lead Product(s): PH-762
Therapeutic Area: Oncology Product Name: PH-762
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 21, 2022
Details:
PH-762, activates immune cells to better recognize and kill cancer cells. It does so by reducing the expression of PD-1, a clinically validated target for immunotherapy. PD-1 is expressed by T-cells and helps keep them from killing other cells, including cancer cells.
Lead Product(s): PH-762
Therapeutic Area: Oncology Product Name: PH-762
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 06, 2022
Details:
PH-762 activates immune cells to better recognize and kill cancer cells by reducing the expression of PD-1, a clinically validated target for immunotherapy. PD-1 is expressed by T cells and prevents them from killing cancer cells.
Lead Product(s): PH-762
Therapeutic Area: Oncology Product Name: PH-762
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 22, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
